Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Unambiguous identification of obesity trials.

Zarin DA, Tse T.

N Engl J Med. 2013 Feb 7;368(6):580-1. doi: 10.1056/NEJMc1215018. No abstract available.

2.

New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

Shyh G, Cheng-Lai A.

Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Review.

PMID:
24304809
3.

The pharmacological and surgical management of adults with obesity.

Ryan DH.

J Fam Pract. 2014 Jul;63(7 Suppl):S21-6. Review. No abstract available.

PMID:
25198216
4.

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.

Halpern B, Faria AM, Halpern A.

Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13. Review.

PMID:
23656337
5.

Overview of new antiobesity drugs.

Hainer V.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6. Review.

PMID:
25100293
6.

Drug treatment of obesity in the cardiovascular patient.

Charakida M, Tousoulis D, Finer N.

Curr Opin Cardiol. 2013 Sep;28(5):584-91. doi: 10.1097/HCO.0b013e3283642a4c. Review.

PMID:
23928924
7.

Obesity Pharmacotherapy.

Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ.

Med Clin North Am. 2018 Jan;102(1):135-148. doi: 10.1016/j.mcna.2017.08.010. Review.

PMID:
29156182
8.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
9.

New pharmacological treatments for the management of obesity.

Hurt RT, Edakkanambeth Varayil J, Ebbert JO.

Curr Gastroenterol Rep. 2014;16(6):394. doi: 10.1007/s11894-014-0394-0. Review.

PMID:
24828101
10.

Medical treatment of obesity: the past, the present and the future.

Bray GA.

Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):665-84. doi: 10.1016/j.bpg.2014.07.015. Epub 2014 Aug 8. Review.

PMID:
25194183
11.

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Bays HE, Gadde KM.

Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738. Review. Erratum in: Drugs Today (Barc). 2012 Jan;48(1):95.

PMID:
22348915
12.

Drug treatment of obesity: current status and future prospects.

Kakkar AK, Dahiya N.

Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Epub 2015 Jan 26. Review.

PMID:
25634851
13.

[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].

Ueno H, Nakazato M.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):753-9. Review. Japanese. No abstract available.

PMID:
24796150
14.

A Comparison of New Pharmacological Agents for the Treatment of Obesity.

Nuffer W, Trujillo JM, Megyeri J.

Ann Pharmacother. 2016 May;50(5):376-88. doi: 10.1177/1060028016634351. Epub 2016 Feb 17. Review.

PMID:
26887340
15.

Pharmacologic therapies for obesity.

Kaplan LM.

Gastroenterol Clin North Am. 2010 Mar;39(1):69-79. doi: 10.1016/j.gtc.2010.01.001. Review.

PMID:
20202580
16.

Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.

Gadde KM, Pritham Raj Y.

Curr Diab Rep. 2017 May;17(5):34. doi: 10.1007/s11892-017-0859-2. Review.

PMID:
28378293
17.

In brief: Phentermine (Lomaira) for weight loss.

[No authors listed]

Med Lett Drugs Ther. 2016 Dec 5;58(1509):158. Review. No abstract available.

PMID:
27906152
18.

Phentermine and topiramate for the management of obesity: a review.

Cosentino G, Conrad AO, Uwaifo GI.

Drug Des Devel Ther. 2011 Apr 5;7:267-78. doi: 10.2147/DDDT.S31443. Print 2013. Review.

19.

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Katsi V, Marketou M, Kallistratos MS, Tousoulis D, Makris T, Manolis AJ, Vardas P, Kallikazaros I.

Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. Review.

PMID:
23565717
20.

Pharmaceutical treatment of obesity.

Blackburn GL, Miller D, Chan S.

Nurs Clin North Am. 1997 Dec;32(4):831-48. Review.

PMID:
9386228

Supplemental Content

Support Center